BACKGROUND: Incidence of primary bilateral breast cancer (BC) is rare and does not exceed 5%. BRCA1/2 mutation carriers diagnosed with breast cancer have a strong life time risk of developing contralateral breast cancer (53% versus 2%). PATIENTS AND METHODS: A group of 108 patients with bilateral breast cancer, who reported at our Cancer Centres from 2000 to 2002, were subjected to genetic testing. Similarities and differences between BRCA1/2 carriers and non-carriers were analysed in terms of family history, pathology of tumour, age of diagnosis, developing contralateral BC and second primary cancer. RESULTS: BRCA1/2 mutations were detected in 32 of 108 patients. Family history of BC was identified in 46.9% of these patients compared with 22.4% of non-carriers (P <0.05). Synchronous BC was diagnosed significantly rarer [4 of 32 (12.5%)] in BRCA1/2 carriers than in the non-carrier group [26 of 76 (34.2%)]. In addition, patients with BRCA mutations were younger when they were diagnosed than non-carriers. BRCA1/2 carriers had a significantly higher incidence of medullary BC (13.6% versus 1.7%) and developed ovarian cancer significantly more frequently than non-carriers (12 of 32 and 1 of 72 patients, respectively). CONCLUSIONS: Patients with bilateral BC having BRCA mutations are significantly younger than non-carriers. They also have a significantly higher family history of BC and an increased risk of developing ovarian cancer. The differences in clinical aspects of BRCA carriers with bilateral BC should be considered in clinical management.
BACKGROUND: Incidence of primary bilateral breast cancer (BC) is rare and does not exceed 5%. BRCA1/2 mutation carriers diagnosed with breast cancer have a strong life time risk of developing contralateral breast cancer (53% versus 2%). PATIENTS AND METHODS: A group of 108 patients with bilateral breast cancer, who reported at our Cancer Centres from 2000 to 2002, were subjected to genetic testing. Similarities and differences between BRCA1/2 carriers and non-carriers were analysed in terms of family history, pathology of tumour, age of diagnosis, developing contralateral BC and second primary cancer. RESULTS:BRCA1/2 mutations were detected in 32 of 108 patients. Family history of BC was identified in 46.9% of these patients compared with 22.4% of non-carriers (P <0.05). Synchronous BC was diagnosed significantly rarer [4 of 32 (12.5%)] in BRCA1/2 carriers than in the non-carrier group [26 of 76 (34.2%)]. In addition, patients with BRCA mutations were younger when they were diagnosed than non-carriers. BRCA1/2 carriers had a significantly higher incidence of medullary BC (13.6% versus 1.7%) and developed ovarian cancer significantly more frequently than non-carriers (12 of 32 and 1 of 72 patients, respectively). CONCLUSIONS:Patients with bilateral BC having BRCA mutations are significantly younger than non-carriers. They also have a significantly higher family history of BC and an increased risk of developing ovarian cancer. The differences in clinical aspects of BRCA carriers with bilateral BC should be considered in clinical management.
Authors: Xavier Gabaldó Barrios; Mª Desamparados Sarabia Meseguer; Miguel Marín Vera; Ana Isabel Sánchez Bermúdez; José Antonio Macías Cerrolaza; Pilar Sánchez Henarejos; Marta Zafra Poves; Mª Rosario García Hernández; Encarna Cuevas Tortosa; Ángeles Aliaga Baño; Verónica Castillo Guardiola; Pedro Martínez Hernández; Isabel Tovar Zapata; Enrique Martínez Barba; Francisco Ayala de la Peña; José Luis Alonso Romero; José Antonio Noguera Velasco; Francisco Ruiz Espejo Journal: Fam Cancer Date: 2017-10 Impact factor: 2.375
Authors: Jonine L Bernstein; Robert W Haile; Marilyn Stovall; John D Boice; Roy E Shore; Bryan Langholz; Duncan C Thomas; Leslie Bernstein; Charles F Lynch; Jorgen H Olsen; Kathleen E Malone; Lene Mellemkjaer; Anne-Lise Borresen-Dale; Barry S Rosenstein; Sharon N Teraoka; Anh T Diep; Susan A Smith; Marinela Capanu; Anne S Reiner; Xiaolin Liang; Richard A Gatti; Patrick Concannon Journal: J Natl Cancer Inst Date: 2010-03-19 Impact factor: 13.506
Authors: Elżbieta Senkus; Jolanta Szade; Beata Pieczyńska; Anna Zaczek; Joanna Pikiel; Katarzyna Sosińska-Mielcarek; Agnieszka Karpińska; Jacek Jassem Journal: Int J Clin Exp Pathol Date: 2013-12-15
Authors: Byung Ho Son; Sei Hyun Ahn; Sung-Won Kim; Eunyoung Kang; Sue K Park; Min Hyuk Lee; Woo-Chul Noh; Lee Su Kim; Yongsik Jung; Ku Sang Kim; Dong-Young Noh; Byung-In Moon; Young Jin Suh; Jeong Eon Lee; Doo Ho Choi; Sung Yong Kim; Sung Hoo Jung; Cha Kyong Yom; Hyde Lee; Jung-Hyun Yang Journal: Breast Cancer Res Treat Date: 2012-03-02 Impact factor: 4.872
Authors: Beth Crawford; Sophie B Adams; Taylor Sittler; Jeroen van den Akker; Salina Chan; Ofri Leitner; Lauren Ryan; Elad Gil; Laura van 't Veer Journal: Breast Cancer Res Treat Date: 2017-03-09 Impact factor: 4.872